Search PubMed⌕ Search

Biomedical subjects

P Scheffler

Publications and source records attributed to P Scheffler.

48 records · Page 3Linked to original sources
PubMed1987

Hemorrheological, micro- and macrocirculatory effects of naftidrofuryl in an acute study: a randomized, placebo-controlled, double-blind individual comparison.

In an intraindividual comparison, the effects of a single dose of 600 mg naftidrofuryl on the fluidity of blood, the conjunctival and transcutaneous partial pressure of oxygen and blood flow through the micro- and macrocirculation were compared with placebo, given in random order to a group of 10 women, apparently healthy apart from showing hemorrheological abnormalities. There were significant increases in erythrocyte deformability, conjunctival partial pressure of oxygen, mean blood flow in the common carotid and femoral arteries. All increases were significant compared to both the initial values and the data in the placebo group. The maximal effect was observed after 1.5 h (capillary erythrocyte velocity, blood flow in the common carotid artery) or 3 h (conjunctival partial pressure of oxygen, blood flow in the femoral artery). After 4.5 h all effects had disappeared.

Adult↗
PubMed1986

[Thrombolytic therapy with ultra-high doses of streptokinase].

Two pilot studies were carried out in patients suffering from acute myocardial infarction. They received high doses of streptokinase and acylated streptokinase-plasminogen activator complex intravenously as a bolus injection. Furthermore, the possibility of using streptokinase bolus therapy was examined in patients with acute vascular occlusion. Due to the limited number and the heterogenicity of cases the results obtained in patients with acute myocardial infarction are to evaluate with some reservation. In patients with acute vascular occlusion streptokinase bolus therapy at high doses proved to be a promising alternative to the conventional therapy.

Coronary Angiography↗
PubMed1986

[Clinical aspects of acquired antithrombin III deficiency].

The significance of acquired antithrombin III (AT III) deficiency must be interpreted in close relation to the underlying disease process. In patients with acute or chronic liver impairment, the AT III activity is related to a decrease of procoagulatory factors, whereas, in protein loss syndromes such as nephrotic syndrome, the AT III indicates an increased risk of thromboembolic events. The effect of oral contraceptives (OC) on AT III levels in young healthy females (n = 30) was determined prospectively. AT III decreases during OC usage could not be related to the estrogen content of the examined oral contraceptives, and there was no parallel decrease of AT III activity and concentration in each type of OC. In a prospective study, the extent of AT III decrease was determined in patients undergoing cardiopulmonary bypass operations (CPB) receiving different anticoagulant schedules during extracorporeal circulation (n = 49). There was no significant influence on the effectiveness of anticoagulation by the observed AT III decreases. AT III deficiency during CPB was primarily the result of hemodilution. However, the AT III kinetics were significantly influenced by the different protamin dosages and were not affected by the different heparin dosages. Correction of diminished AT III levels by substitution of AT III concentrates is beneficial in cases, in which an interruption of an enhanced coagulatory process such as disseminated intravascular coagulation is necessary or in patients requiring high dosage heparinization as in deep vein thrombosis. In those cases the quality of AT III correction correlates to the course of the disease. However, the potency of concentrates as well as the individual AT III recovery and half-life must be considered for an appropriate treatment with AT III substitution.

Adult↗
PubMed1986

[Fibrinolytic treatment of deep vein thrombosis and lung embolism].

Selective evaluation prior to determining the indication for thrombolytic therapy is just as important for therapeutic success as choosing the appropriate fibrinolytic agent. During this initial stage, the localization, age, extension, and possible consequences of the thrombosis must be determined with suitable as well as specific methods. Selection of the fibrinolytic agent and careful monitoring of the thrombolysis should ensure a maximum therapeutic effect with a minimum of bleeding complications.

Fibrinolysis↗
PubMed1985

Gray platelet syndrome: selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover.

Clinical and laboratory studies of two siblings, both suffering from gray platelet syndrome (GPS) are described. The patients had a mild bleeding disorder, their platelets were blue-gray in panoptic stains, and alpha-granules were markedly reduced, as shown by electron microscopy. The platelet content of platelet factor 4 and that of beta-thromboglobulin were significantly reduced (3%-7% of normal). Platelet count was decreased (33-150 X 10(9)/1) and small platelets were increased in platelet volume distribution. Bleeding time was prolonged on most occasions. Bone marrow aspiration was performed in one patient and revealed increased reticulin fibers, however, megakaryocyte count was normal. The mean platelet survival was 4.8 days using 111indium-labelled platelets. In this patient, platelet-associated IgG was within the normal range. Prednisone therapy failed to increase platelet count. Dental surgery was performed under cover of desmopressin and no bleeding complication occurred; however, no improvement of bleeding time was observed. The patient delivered a healthy male infant without hemorrhaging while under concurrent platelet transfusion therapy.

Adult↗
PubMed1975

The effect of purine and pyrimidine analogues and virazole on adenovirus replication.

The multiplication of adenovirus 19 in HeLa cells was inhibited by various purine and pyrimidine analogues and by virazole. The formation of infectious virus and of capsid proteins (haemagglutin, group-specific complement-fixing antigen) was inhibited to the same degree, while the viral cytopathic effect (CPE) was not inhibited. The reversibility of the inhibition after removal of the substances was more complete for purine than for pyrimidine analogues. The inhibition was counteracted by simulataneous addition of the corresponding nucleosides. Adenosine was more effected than guanosine against purine analogues; both were partially effective against virazole, but none of them against arabinofuranosyladenine. The time-dependence of inhibition, the ensuing eclipse period after removal of the inhibitors, and the successive application of two inhibitors led to the conclusion that most of them affect the viral multiplication mainly by inhibition of DNA synthesis. Azacytidine inhibits the synthesis of structural proteins as well.

Adenoviridae↗
PubMedDate not supplied

Control of therapy with microcirculatory and phlebotropically active drugs in patients with congenital and acquired venous insufficiency.

During the treatment of two patients with Klippel-Trenaunay syndrome interesting observations of the efficacy and the side effects of DHE were made. This led to the decision to carry out a validity study in 12 patients suffering from chronic venous insufficiency (CVI). The patients were treated with 0.25 mg or 0.5 DHE intravenously, and after that with 7.5 mg orally for one week. Before and after treatment measurements of venous capacity, microcirculatory parameters and rheological parameters were performed. Following the i.v. injection of 0.25 to 0.5 mg DHE the venous capacity decreased significantly in a dose-dependent way. The flow of erythrocytes in capillaries measured under resting condition was significantly lower and peak flow of reactive hyperemia decreased. No relation was found between the dose of DHE administered and the particular side effects (stomach trouble, increase in diastolic blood pressure) in 2 of the 12 patients. After oral treatment patients showed signs of subjective improvement of their complaints. On the basis of the results, the validity of non-invasive angiological tests is discussed.

Administration, Oral↗
PubMedDate not supplied

Thrombus formation in deep venous thrombosis. A clinical approach to diagnosis and control of lysis efficacy.

The efficacy of fibrinolysis in deep venous thrombosis (DVT) depends on the age and organization of the thrombus as well as its localization. Up to now, indication for lysis therapy is defined according to the duration of clinical symptoms (less than 7 days). Our lysis results in urokinase therapy (n = 87) with high-dose and long-term regimen (mean 7.8 days), however, have shown no correlation between the duration of clinical symptoms (up to six weeks) and lysis efficacy (p less than 0.05). Therefore phlebographic criteria were established to allow the differentiation of fibrinolytic therapy depending on the site of the thrombus, its localization and the formation of collateral veins. In order to determine the state of thrombus organization, we used a new ultrasound Duplex system device (ARTIS, 7.5 Mhz, Picker International). In vivo experiments with induced thrombosis in human vena saphena magna demonstrate that echodensity of thrombi in ultrasound starts at the 11th-15th day. These findings are in good agreement with pathological studies of thrombus formation. Recent results of 24 patients with DVT indicate that echodensity of thrombus in ultrasound correlates with the course of organization and the efficacy of later lysis therapy.

Adult↗